Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Zacks News
Teva Migraine Candidate Succeeds in Second Phase III Study
by Zacks Equity Research
Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.
Regeneron Announces Positive Data on Carcinoma Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Teva's Migraine Candidate TEV-48125 Positive in Phase III
by Zacks Equity Research
Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period
Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up
by Zacks Equity Research
Teva???s first quarter earnings (including equity compensation expenses), came in at $1.03 per share, in-line with the consensus estimate.
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
by Swarup Gupta
Mylan and Teva are scheduled to report on May 10 and May 11
Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View
by Zacks Equity Research
Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
by Zacks Equity Research
Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).
Allergan (AGN) Presents Mixed Depression Data on Botox
by Zacks Equity Research
Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).
Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst
by Zacks Equity Research
Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Teva's Austedo Gets FDA Nod for Huntington Disease Treatment
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).
Allergan Acne Candidate Meets Endpoints in Phase III Studies
by Zacks Equity Research
Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
Teva Pharma Denies Rumors of Global Workforce Reduction
by Zacks Equity Research
According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
Allergan's Restasis Now Available in Multidose Bottle in U.S.
by Zacks Equity Research
Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
by Zacks Equity Research
Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
by Zacks Equity Research
Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.